TG Therapeutics ( (TGTX) ) has released its Q2 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, with a particular emphasis on therapies for multiple sclerosis (MS). The company is known for its innovative approach in the healthcare sector, particularly with its flagship product BRIUMVI, an anti-CD20 monoclonal antibody therapy.
In its latest earnings report, TG Therapeutics announced a significant increase in revenue for the second quarter of 2025, driven primarily by the strong performance of BRIUMVI in the U.S. market. The company has raised its full-year revenue guidance for BRIUMVI, reflecting its confidence in the product’s market potential and ongoing growth.
Key financial highlights include a total revenue of $141.1 million for the second quarter, with BRIUMVI contributing $138.8 million, marking a 91% growth compared to the same period last year. The company also reported a net income of $28.2 million for the quarter, a substantial increase from the previous year’s $6.9 million. Additionally, TG Therapeutics has expanded BRIUMVI’s commercialization internationally, with approvals in the EU, UK, Switzerland, and Australia.
The company is actively pursuing further development of BRIUMVI, including a subcutaneous formulation and a consolidated dosing regimen, which are currently under study. These advancements are expected to enhance BRIUMVI’s market position and redefine treatment expectations for MS patients.
Looking ahead, TG Therapeutics remains optimistic about its growth trajectory, supported by strong physician confidence and patient experiences with BRIUMVI. The company anticipates that its strategic initiatives and ongoing clinical trials will continue to drive revenue growth and solidify its position in the biopharmaceutical market.